Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DMX-200 Phase 3 trial in focal segmental glomerulosclerosis
ACTRN12622000066785Phase 3Recruiting
- Sponsor
- Dimerix
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial of repagermanium in focal segmental glomerulosclerosis (FSGS) (3 arms), sponsored by Dimerix. Primary endpoints: Percent change in urine protein-creatinine ratio, eGFR slope and 1 more. Started May 2022; status: recruiting.
02
Drugs
repagermanium
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on ACTRN12622000066785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000066785.